Search

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center (MSK), and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery.

… Thursday, September 29, 2016 VIDEO | 00:49 CART Cells That Function as Micro-Pharmacies Dr. Hans Guido Wendel explains the untapped potential of CAR T cells to act as targeted delivery vehicles that can function as “micro-pharmacies” for precise therapeutic delivery. Video Details There has been much

MSK worked tirelessly to provide the COVID-19 vaccine to patients and employees.

… Thursday, April 1, 2021 Giving COVID-19 vaccines to MSK patients has been an urgent mission for the hospital this year. Knowing that patients are anxious about getting protected from the virus, which is especially devastating to people with cancer, the MSK COVID-19 Vaccine Care Team and countless other

Memorial Sloan Kettering Cancer Center (MSK) today announced that Kenneth Offit, MD, MPH, and Ross L. Levine, MD, have been elected as Fellows of the AACR Academy, one of the highest honors bestowed by the American Association for Cancer Research (AACR).

… Tuesday, January 27, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced that  Kenneth Offit, MD, MPH , and  Ross L. Levine, MD , have been elected as  Fellows of the AACR Academy, one of the highest honors bestowed by the  American Association for Cancer Research (AACR). Election to the

Thousands of technology professionals from around the world recently gathered in Long Beach, California, for the sold-out Neural Information Processing Systems (NIPS) conference, a multi-track machine learning, artificial intelligence, and computational neuroscience event featuring talks, demonstrations, symposia and oral / poster presentations, along with several workshops. Leaders in artificial intelligence, machine learning, and data engineering from Memorial Sloan Kettering attended NIPS and announced the winner of a unique competition created by MSK, Classifying Clinically Actionable Genetic Mutations. For more information and to set up interviews or access photos and video, email [email protected].

… Monday, December 11, 2017 Thousands of technology professionals from around the world recently gathered in Long Beach, California, for the sold-out Neural Information Processing Systems (NIPS) conference, a multi-track machine learning, artificial intelligence, and computational neuroscience event featuring

MSK experts co-authored a piece in Targeted Oncology about the findings from a recent clinical trial.

… Tuesday, May 11, 2021 MSK radiation oncologists Kaveh Zakeri, Yao Yu , and Nancy Lee co-authored an article published on May 6 in Targeted Oncology that discusses a recent study led by Dr. Lee. The study , published in April in the journal Lancet Oncology , found that the addition of immunotherapy to

Three winners of the first-ever Breakthrough Prizes — Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.

… Monday, May 12, 2014 New Annual Life Sciences Award for Postdoctoral Trainees Established Following last year’s announcement of the first-ever Breakthrough Prizes, established by a well-known group of Silicon Valley entrepreneurs to celebrate scientists and encourage careers in the field, the winners

New research has found that a precancerous blood condition can linger undetected for more than 20 years.

… Monday, October 23, 2017 Summary New research has found that a precancerous blood condition can linger undetected for more than 20 years. The findings suggest that screening tests may be appropriate for some people. The medical community is always learning more about the hereditary nature of cancer.

Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly.

… Wednesday, July 30, 2014 Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard J. O’Reilly, MD , a world-renowned pioneer in the development of transplant

A team of Memorial Sloan Kettering investigators has reported for the first time a novel strategy to coax human embryonic stem cells (HESCs) to develop into cells that could potentially be used to repair the musculoskeletal system, including bone, cartilage, and muscle.

… Monday, June 25, 2007 Summary A team of Memorial Sloan Kettering investigators has reported for the first time a novel strategy to coax human embryonic stem cells (HESCs) to develop into cells that could potentially be used to repair the musculoskeletal system, including bone, cartilage, and muscle.

For some students, summer means fun in the sand, surf, and sun. But the high school and college students accepted into one of Memorial Sloan Kettering Cancer Center’s summer internship programs have a far more meaningful answer to the perennial question, “What did you do this summer?”

… Wednesday, August 18, 2021 For some students, summer means fun in the sand, surf, and sun. But the high school and college students accepted into one of Memorial Sloan Kettering Cancer Center’s summer internship programs have a far more meaningful answer to the perennial question, “What did you do this